Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
diffuse large B-cell lymphoma (DLBCL)
Biotech
Merck ADC RORs into phase 3 with 100% complete response rate
Merck trumpeted a 100% complete response rate but also reported safety signals that informed the decision to take the low dose into phase 3.
Nick Paul Taylor
Dec 9, 2024 5:03am
Regeneron seeks clarity on confirmatory trials after FDA hurdle
Mar 29, 2024 5:00am
ASH: Regeneron’s near-approval bispecific shines again
Dec 11, 2023 5:25am
Cancer biotech IMV hunts for a deal as its cash clock ticks down
Mar 16, 2023 8:28am
ASH: Regeneron lymphoma med scores but safety muffles excitement
Dec 12, 2022 5:30pm
ASH: Regeneron readies bispecific data—but deaths cast shadow
Dec 12, 2022 7:30am
